You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer

Authors

  • No-Joon Song Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Karthik B Chakravarthy Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Hyeongseon Jeon Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Chelsea Bolyard Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Kelsi Reynolds Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Kevin P Weller Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Sarah Reisinger The Ohio State University Wexner Medical Center, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Yi Wang Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Anqi Li Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Sizun Jiang Department of Pathology, Stanford University, Stanford, California, USACenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Qin Ma Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Dan H Barouch Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Mark P Rubinstein Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Peter G Shields The Ohio State University Wexner Medical Center, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Eugene M Oltz Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Dongjun Chung Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USADepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Zihai Li Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center Arthur G James Cancer Hospital and Richard J Solove Research Institute, Columbus, Ohio, USADivision of Medical Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA PubMed articlesGoogle scholar articles

Citation

Song N, Chakravarthy KB, Jeon H, et al
mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer
Journal for ImmunoTherapy of Cancer 2024;12:e007922. doi: 10.1136/jitc-2023-007922
Online issue publication 
January 04, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.